William Blair Downgrades Sequenom (SQNM) to Market Perform

Go back to William Blair Downgrades Sequenom (SQNM) to Market Perform

Jefferies Downgrades Sequenom (SQNM) to Hold

September 30, 2015 7:32 AM EDT

Jefferies downgraded Sequenom (NASDAQ: SQNM) from Buy to Hold with a price target of $1.50 (from $5.00).

Analyst Brandon Couillard commented, "Our prior Buy rating had been predicated on: 1) visibility to positive cash flow; and, 2) low valuation relative to other NIPT targets. However, after... More

Ladenburg Thalmann Downgrades Sequenom (SQNM) to Sell

September 29, 2015 7:17 AM EDT

Ladenburg Thalmann downgraded Sequenom (NASDAQ: SQNM) from Neutral to Sell.

For an analyst ratings summary and ratings history on Sequenom click here. For more ratings news on Sequenom click here.

Shares of Sequenom closed at $1.92 yesterday.

... More

Sequenom (SQNM) Lowers 2nd-Half Revenue Outlook

September 25, 2015 7:06 AM EDT

Sequenom (NASDAQ: SQNM) is updating its revenue expectations for the second half of the year to a range between $57 million and $61 million, bringing 2015 annual revenue expectations to a range between $127 million and $131 million. This versus the consensus of $141 million.

Drivers for the updated expectations include increased competition and price... More

Sequenom (SQNM) Guides FY Revenue Below Street Views

September 25, 2015 7:05 AM EDT

Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, provides its current revenue outlook for the second half of 2015.

The Company is updating its revenue expectations for the second half of the year to a range between $57 million and $61 million, bringing 2015 annual revenue... More